一分钟看懂
这是一项关于晚期实体瘤的I 期 / II 期研究，登记的药物或干预包括WJB001 Capsules+Paclitaxel/Paclitaxel-albumin；WJB001 Capsules+carboplatin/Nedaplatin；WJB001 Capsules+Paclitaxel+carboplatin；WJB001 Capsules+，当前状态为招募中。登记地点显示中国北京、福州、广州、南宁等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
WJB001 Capsules+Paclitaxel/Paclitaxel-albumin；WJB001 Capsules+carboplatin/Nedaplatin；WJB001 Capsules+Paclitaxel+carboplatin；WJB001 Capsules+Niraparib；WJB001 Capsules+Bevacizumab；WJB001 Capsules+JS207/JS001；WJB001 Capsules+Paclitaxel+carboplatin+JS207/Toripalimab · I 期 / II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Cancer Hospital Chinese Academy of Medical Sciences · 北京
- Fujian Cancer Hospital · 福州
- Sun Yat-sen University Cancer Center · 广州
- Tumor Hospital Affiliated to Guangxi Medical University · 南宁
- Sun Yat-sen Hospital, Sun Yat-sen University · 广州
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · 武汉
- Hunan Cancer Hospital · 长沙
- Liaoning Cancer Hospital · 沈阳
- The First Affiliated Hospital of China Medical University · 沈阳
- The Second Affiliated Hospital of Zhejiang University School of Medicine · 杭州
公开的入选条件
- Participants must meet all of the following inclusion criteria:
- 1. Participants voluntarily participate in this study with full informed consent and sign an informed consent form（ICF）.
- 2. Age ≥ 18 years old, No gender limitation,witih BMI (Body Mass Index) ≥ 18.5.
- 3. Patients diagnosed with Advanced solid tumors confirmed by pathology and/or cytology, must meet the following criteria:
- 1. For the detection of biomarkers such as CCNE1,tumor tissue samples must be provided from the patient
- 2. CCNE1 overexpression confirmed by central laboratory immunohistochemistry (IHC) in tumor tissue
- 3. Have failed or are intolerant to standard treatments or have no available standard treatments options(Applicable to Dose escalation phase)
- 4. For patients with platinum-sensitive or platinum-resistant recurrent advanced high-grade serous ovarian cancer(HGSOC), fallopian tube cancer, or peritoneal cancer, as well as advanced uterine serous carcinoma (USC)
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06953323；登记信息更新于 2026-09-17。